We raised 2 million Euros from
technology focused venture capital fund
ACT Venture Partners.
Our production facility was
granted GMP license for clinical batch
lyophilized oncology drugs.
In consequence of promising results from
pre-clinical studies, we started
RS-0139’s phase-I clinical trial in NSCLC.
We raised 12 million USD in our
Series-A investment round from Gen İlaç,
OneLife Ventures and Eczacıbaşı Momentum.